Adaptimmune therapeutics plc ( adp ) is a cell therapy company that has been successfully initiated in the past 20 years. it is now now being able to accelerate the execution of the first - generation sarcoma and a second - generation sarcoma trial. this is the first phase of the Adaptimmune program and is now being initiated by the end of the year. the adp trial is currently occurring at one billion cells without evidence of hepatotoxicity and a combination trial with low-dose radiation to improve the depth and durability of responses. the adp trial is currently occurring at one billion cells without evidence of hepatotoxicity and a combination trial with low-dose radiation to improve the depth and durability of responses. the adp trial is currently occurring at one billion cells without evidence of hepatotoxicity and a combination trial with low-dose radiation to improve the depth and durability of responses. the adp trial will be now being launched by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year. the adp trial will be completed by the end of the year.